Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes

Some oral anti-hyperglycemic drugs, including gliptins that inhibit dipeptidyl peptidase 4 (DPP4), have been linked to the increased risk of heart failure (HF) in type-2 diabetic patients. While the cardiovascular safety trial, TECOS, revealed no link between sitagliptin and the risk of HF, a substa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Front Physiol
Autores principales: Koyani, Chintan N., Trummer, Christopher, Shrestha, Niroj, Scheruebel, Susanne, Bourgeois, Benjamin, Plastira, Ioanna, Kickmaier, Sandra, Sourij, Harald, Rainer, Peter P., Madl, Tobias, Sattler, Wolfgang, Pelzmann, Brigitte, Malle, Ernst, von Lewinski, Dirk
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2018
Materias:
Physiology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6246635/
https://ncbi.nlm.nih.gov/pubmed/30487758
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphys.2018.01622
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares